MedTrace Logo

A Study of ADH300004 and 5-Fluorouracil in Locally Advanced, Recurrent, or Metastatic Hepatocellular Carcinoma

NCT00319683 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2008-12-15

No results posted yet for this study

Summary

5-fluorouracil (5-FU), one of the most actively investigated anti-cancer drugs, is rapidly inactivated by the enzyme dihydropyrimidine dehydrogenase (DPD). ADH300004 blocks DPD. This study will test the safety and effects of oral ADH300004 14 hours prior to oral 5-FU in subjects with locally advanced, recurrent, or metastatic hepatocellular carcinoma.

Conditions

Interventions

DRUG

ADH300004

Sponsors & Collaborators

  • Adherex Technologies, Inc.

    lead INDUSTRY

Principal Investigators

  • Jacqueline Whang-Peng, MD · National Health Research Institute, Ward Veterans General Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States
  • Singapore
  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00319683 on ClinicalTrials.gov